Literature DB >> 24817941

Lepidic and micropapillary growth pattern and expression of Napsin A can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup.

Xin Yang1, Yu Liu2, Fang Lian1, Lei Guo1, Peng Wen1, Xiu-Yun Liu1, Dong-Mei Lin1.   

Abstract

Histologic categories and related growth pattern proposed by IASLC/ATS/ERS classification has been reported to be prognostically important in lung adenocarcinoma. Thyroid transcription factor-1 (TTF1) and Napsin A have been investigated as potential prognostic parameters with conflicting results. A total of 211 cases with stage I lung adenocarcinoma were analyzed according to the IASLC/ATS/ERS classification with slight modifications. Expression levels of TTF1 and Napsin A were evaluated by immunohistochemistry. In univariate analyses, we found female sex (p=0.009), lepidic growth pattern (P=0.011) and lack of micropapillary pattern (P=0.048) were favorable predictor significantly associated with disease-free survival (DFS). Lack of mitosis (P=0.044) and Napsin A expression (P=0.031) were favorable predictors for overall survival (OS). Tumors with a maximum diameter≤2 cm had both longer DFS (P=0.008) and OS (P=0.020). Negative TTF1 expression indicated increased risk of death, but failure in statistical significance (P=0.215). After multivariate analysis, histologic subtype, tumor size and gender were identified as independent predictor for DFS (RR: 0.343, 3.697, 0.494; P=0.006, 0.029, 0.019), no feature was found as an independent predictor for overall survival (P>0.05). To conclude, lepidic growth pattern, female sex and tumor size≤2 cm are independent favorable predictors for tumor recurrence, tumors with more than 5% percentage of lepidic growth pattern will have a better prognosis than absence, in early-stage lung adenocarcinoma.

Entities:  

Keywords:  IASLC/ATS/ERS classification; Napsin A; Stage I; TTF1; lung adenocarcinoma; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24817941      PMCID: PMC4014225     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.

Authors:  T Koga; S Hashimoto; K Sugio; I Yoshino; S Mojtahedzadeh; Y Matsuo; Y Yonemitsu; K Sugimachi; K Sueishi
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

2.  Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification.

Authors:  Prudence A Russell; Zoe Wainer; Gavin M Wright; Marissa Daniels; Matthew Conron; Richard A Williams
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

3.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

4.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Authors:  Akihiko Yoshizawa; Noriko Motoi; Gregory J Riely; Cami S Sima; William L Gerald; Mark G Kris; Bernard J Park; Valerie W Rusch; William D Travis
Journal:  Mod Pathol       Date:  2011-01-21       Impact factor: 7.842

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

6.  Pulmonary adenocarcinomas: classification and reporting.

Authors:  Keith M Kerr
Journal:  Histopathology       Date:  2009-01       Impact factor: 5.087

7.  Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy.

Authors:  Marco Chilosi; Bruno Murer
Journal:  Arch Pathol Lab Med       Date:  2010-01       Impact factor: 5.534

Review 8.  Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.

Authors:  G M Strauss; D J Kwiatkowski; D H Harpole; T J Lynch; A T Skarin; D J Sugarbaker
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

9.  Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.

Authors:  Valsamo K Anagnostou; Konstantinos N Syrigos; Gerold Bepler; Robert J Homer; David L Rimm
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis.

Authors:  Yoichi Anami; Tatsuo Iijima; Kenji Suzuki; Jun Yokota; Yuko Minami; Hiromi Kobayashi; Kaishi Satomi; Yoshimasa Nakazato; Masafumi Okada; Masayuki Noguchi
Journal:  J Thorac Oncol       Date:  2009-08       Impact factor: 15.609

View more
  7 in total

1.  Prognostic factors of patients with pathologic stage I lung adenocarcinoma.

Authors:  Ying-Yi Chen; Tsai-Wang Huang
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma.

Authors:  Jung-Soo Pyo; Joo Heon Kim
Journal:  Pathol Oncol Res       Date:  2017-07-06       Impact factor: 3.201

3.  The Diagnostic Potential of SHOX2 and RASSF1A DNA Methylation in Early Lung Adenocarcinoma.

Authors:  Hong Gao; Jun Yang; Lu He; Wei Wang; Yanhong Liu; Yue Hu; Meiling Ge; Jie Ding; Qing Ye
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

4.  Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis.

Authors:  Yue Zhao; Rui Wang; Xuxia Shen; Yunjian Pan; Chao Cheng; Yuan Li; Lei Shen; Yang Zhang; Hang Li; Difan Zheng; Ting Ye; Shanbo Zheng; Yihua Sun; Haiquan Chen
Journal:  Ann Surg Oncol       Date:  2016-02-02       Impact factor: 5.344

5.  Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations.

Authors:  Ruiguang Zhang; Yan Li; Xiu Nie; Xiaorong Dong; Gang Wu
Journal:  Onco Targets Ther       Date:  2016-01-18       Impact factor: 4.147

6.  Pathologic heterogeneity of lung adenocarcinomas: A novel pathologic index predicts survival.

Authors:  Geewon Lee; E-Ryung Choi; Ho Yun Lee; Ji Yun Jeong; Joong Hyun Ahn; Seonwoo Kim; Jungmin Bae; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jaeil Zo; Kyung Soo Lee; Young Mog Shim
Journal:  Oncotarget       Date:  2016-10-25

7.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.